Abstract Details

Title Abnormal Variable Contrast Acuity in Parkinson's Disease

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 143

Objective

Background BACKGROUND: Visual contrast acuity is reduced in PD due to loss of dopamine in amacrine-containing retina cells. An iPad version of the Variable Contrast Acuity Chart recently became available and has not been tested in PD patients.

Design/Methods DESIGN/METHODS: Twelve PD and 46 controls were enrolled in the study. All were participants in the Arizona PD Consortium/Banner Sun Health Research Institute Brain and Body Donation Program. Participants viewed the Variable Contrast Acuity Chart on an iPad at distances of 40cm and 2m, with 100% and 2.5% contrast at each distance. Visual acuity at each condition was converted into a numeric contrast acuity (CA) score using a predetermined scale. Mean scores of the PD and control groups adjusted for age and sex were compared using a general linear model.

Results RESULTS: The mean age was younger in PD (74.3±8.1 years) vs. Control (82.8±7.2 years). More men were in the PD group (75% PD; 24% Control). The mean PD duration was 10.1+5.2 years (range 1.9-17 years). Adjusting for age and sex, PD patients had statistically lower scores (worse vision) than controls in two test conditions: 100% contrast at 40cm (CA mean score = 78 for PD vs. 84 for controls, p=0.02) and 2.5% contrast at 2m (16 vs. 28, p=0.001), with a trend in the other two conditions: 100% contrast at 2m (53 vs. 58, p=0.14) and 2.5% contrast at 40cm (42 vs. 52, p=0.06).

Conclusions CONCLUSIONS: In this preliminary study, Parkinson's disease patients were found to have more difficulty in reading the Variable Contrast Acuity Chart compared to controls. The iPad version of this eye chart is adjustable for distances and contrast levels, and may be a rapid tool for quantifying visual changes in Parkinson's disease.

Authors/Disclosures
Tanya Lin, MD PRESENTER	Dr. Lin has nothing to disclose.
Charles H. Adler, MD, PhD, FAAN (Mayo Clinic Arizona)	Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Adler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CND Life Sci. Dr. Adler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precon. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Dr. Adler has received research support from NIH. The institution of Dr. Adler has received research support from Michael J. Fox Foundation. The institution of Dr. Adler has received research support from Arizona Biomedical Research Commission. Dr. Adler has received publishing royalties from a publication relating to health care.
Joseph Hentz (Mayo Clinic)	No disclosure on file
Jennifer Adler	No disclosure on file
James M. Meyer, PharmD (Marathon Pharmaceuticals, LLC)	No disclosure on file
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine)	An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia.
Steven Galetta, MD, FAAN (NYU Langone Medical Center)	Dr. Galetta has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��